Search

everythinglearnresearchcommunity

for

Search:↓

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Scalp cooling can prevent hair loss in 65% of chemotherapy patients, especially effective in breast cancer patients and certain chemotherapy types.

People undergoing chemotherapy need better support and information to cope with hair loss.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

Cannabinoid receptor-1 signaling is essential for the survival and growth of human hair follicle stem cells.

The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.

Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.

Cancer treatments often cause hair loss and damage, affecting patients' mental health.

Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.

The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

PHAT may improve hair growth better than PRP alone.

A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.

Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.

Chemotherapy patients don't all lose their hair due to factors like hair growth rates, age, genetics, and the type of drugs used.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

Blocking the Mitochondrial Pyruvate Carrier causes stress in hair follicles, which can be reduced by an ISR inhibitor.

2-deoxy-D-ribose gel may help regrow hair in cases of hair loss.

Nails can reveal important health information about skin and body conditions.

No method fully prevents hair loss from chemotherapy, but some methods can reduce it and improve quality of life.

Some drugs can cause reversible hair loss, but certain chemotherapy drugs may lead to permanent hair loss; drugs can also change hair color and texture.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.